The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

33 ARCH STREET, 26TH FLOOR, BOSTON MA 02110-1447, USA
Tel:
Work +1 617 406 6000
Fax:
Fax +1 617 406 6100
Email:
Web:
www.dlapiper.com

Mike McGurk

Tel:
Work +1 617 406 6083
Email:
DLA Piper LLP (US)

Work Department

Intellectual Property

Position

Partner

Career

Mike McGurk has more than 30 years of experience in virtually all aspects of patent law. Working with clients ranging from small start-ups to large Fortune 100 companies, he provides counsel in due diligence matters, global portfolio development and adversarial proceedings, including litigation, post-grant reviews, interferences and re-examinations. Mike works primarily with pharmaceutical, chemical, medical device and mechanical technology businesses.

Mike's practice is informed by his background as a patent examiner in the chemical arts for the United States Patent and Trademark Office (USPTO), as a litigator for ten years, and as an expert in due diligence matters. He regularly provides strategic litigation counseling support to clients across the nation, and has handled numerous patent matters before the Patent Trial and Appeal Board of the USPTO. His extensive due diligence experience includes pre-litigation, acquisition, in-license, freedom-to-operate product and/or process clearance, design around, validity and patentability matters. Mike works with teams having the appropriate technical and legal abilities.

Education

JD, George Washington University Law School; BS, University of Delaware


United States: Intellectual property

Patents: licensing

Within: Leading lawyers

Mike McGurk - DLA Piper LLP (US)

Within: Patents: licensing

With a particular strong standing in the life sciences and technology industries, DLA Piper LLP (US) demonstrates expertise in transactional licensing, including mergers and acquisitions, spin-offs, and asset sales, flanked by a strong due diligence track record; settlement negotiations, in particular with non-practicing entities, as well as domestic and international research and development agreements are other focus areas. The San Diego-based Mark Lehberg led advice to Qualcomm on a large number of cross-border licence agreements in the context of its $3bn joint venture with TDK. The team also assisted Geneius Biotechnology with the creation of its patent portfolio in the personalized oncology therapeutic platform space. In other work, San Diego’s Lisa Haile was key in obtaining a notice of allowance for Revolution Contraceptive from the Parsemus Foundation regarding a reversible male contraceptive. The Philadelphia-based Darius Gambino and Mike McGurk in Boston are other noteworthy practitioners. Clients also include Nanotherapeutics and the University of Texas at Austin.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to